Compare AbbVie Inc (ABBV) vs Newmont Corporation (NEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Newmont Corporation — how do they compare? AbbVie Inc trades at $253.58 (market cap $449.91B), while Newmont Corporation trades at $92.4 (market cap $101.48B). The key difference: AbbVie Inc is far larger — about 4.4× Newmont Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | NEM | |
|---|---|---|
Market Cap | $449.91B | $101.48B |
Sector | Health | Basic Materials |
52-Week High | $261.07 | $131.95 |
52-Week Low | $184.85 | $57.35 |
Enterprise Value | $513.38B | $98.23B |
Dividend Yield | 2.72% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Newmont Corporation (NEM) trades at $95.06, down 2.04% over 24 hours amid a bearish technical signal. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $2.90 versus $2.07 expected, revenue growth to $22.67 billion in 2025, and robust cash flow of $10.33 billion from operations. Analyst consensus is bullish with a $144.00 price target and 75% buy ratings, though recent gold price volatility has pressured shares.
The outlook remains positive due to low valuation multiples (P/E 12.74, EV/EBITDA 6.27) and record free cash flow, but risks include gold market fluctuations and execution of expansion projects. The stock presents a value opportunity for long-term investors, supported by a strong balance sheet and dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
